General Information of Drug (ID: DMEPQ76)

Drug Name
CVN424 Drug Info
Synonyms
CVN424; XO01711URG; CVN-424; 2254706-21-1; UNII-XO01711URG; CHEMBL4778540; Ethanone, 1-(2-(4-(2,4-difluorophenoxy)-1-piperidinyl)-7,8-dihydro-3-(((3R)-tetrahydro-3-furanyl)amino)pyrido(3,4-b)pyrazin-6(5H)-yl)-; 1-[2-[4-(2,4-difluorophenoxy)piperidin-1-yl]-3-[[(3R)-oxolan-3-yl]amino]-7,8-dihydro-5H-pyrido[3,4-b]pyrazin-6-yl]ethanone; SCHEMBL20584477; GTPL11514; BDBM50582450; AKOS040759781; AT37427; HY-134661A; compound 6i [PMID: 33861086]; MS-28775; CS-0163733; Z3664677849
Indication
Disease Entry ICD 11 Status REF
Parkinson disease 8A00.0 Phase 2 [1]
Cross-matching ID
PubChem CID
137359492
TTD Drug ID
DMEPQ76

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
G-protein coupled receptor 6 (GPR6) TTSDWS5 GPR6_HUMAN Agonist [2]

References

1 ClinicalTrials.gov (NCT04191577) A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations. U.S.National Institutes of Health.
2 Development of CVN424: A Selective and Novel GPR6 Inverse Agonist Effective in Models of Parkinson Disease. J Pharmacol Exp Ther. 2021 Jun;377(3):407-416.